| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f1ab60393ecb1347289a870f153fce4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f2d0f6a6161efb05b2ef69fab54ff42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95cba80ebbf1517306d8c6cba42b59f6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-185 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-01 |
| filingDate |
2010-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_063144c1a32a69c1dbf81501f1bf4105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75800db9e793c003ed98d5b8e29eb2e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b6eae51674667e869caa170fce4530e |
| publicationDate |
2013-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8609897-B2 |
| titleOfInvention |
Trifluoromethylsulfonamide gamma secretase inhibitor |
| abstract |
The present invention is directed to a novel trifluoromethylsulfonamide derivative which inhibits the processing of APP by the putative γ-secretase and thus is useful in the treatment or prevention of Alzheimer's disease. This compound possesses favorable pharmacokinetic properties in higher species (rhesus) and thus can be dosed on an intermittent dosing regiment (e.g., once weekly). When dosed on such a regiment the compound exhibits significant and continuous Aβ lowering without the manifestation of Notch associated gastrointestinal toxicity for extended periods, e.g., 7 days. Pharmaceutical compositions and methods of use are also included. |
| priorityDate |
2009-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |